AviadoBio

AviadoBio, founded in 2019 and headquartered in the United Kingdom, is making waves in the biotech industry with its mission to revolutionize gene therapy for neurodegenerative disorders, focusing on conditions like frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

With a strong foundation in groundbreaking science originating from King’s College London and the UK Dementia Research Institute, AviadoBio has crafted a suite of proprietary gene therapy platforms that target the brain with precision. Their unique, neuroanatomy-led approach aims not just to treat but to halt or even reverse the progression of neurodegenerative diseases.

Having secured a $20.00M Corporate Round investment in October 2024 led by Astellas Pharma, the company continues to demonstrate its potential by advancing its technologies towards life-changing therapies. Investors would be wise to consider AviadoBio as a promising venture in the nuanced field of healthcare and biotechnology.